Overcoming endocrine resistance in metastatic hormone receptor-positive breast cancer
Anishka D'Souza1, Darcy Spicer1, Janice Lu2
1USC Norris Comprehensive Cancer Center, 1441 Eastlake Avenue, Los Angeles, CA, 90033, USA.
Abstract:
Endocrine therapy has historically formed the basis of treatment of metastatic hormone receptor-positive breast cancer. The development of endocrine resistance has led to the development of newer endocrine drug combinations. Use of the CDK4/6 inhibitors has significantly improved progression-free survival in this group of patients. There are multiple studies of the use of P13K inhibitors and mTOR inhibitors for use as subsequent lines of therapy, particularly for endocrine resistance. The optimal sequencing of therapy should be based on medical comorbidities, prior adjuvant therapies, quality of life, side-effect profile, and disease-free interval.
Insights
Treatment for metastatic hormone receptor-positive breast cancer now includes CDK4/6 inhibitors, improving progression-free survival. Further research explores PI3K and mTOR inhibitors for endocrine resistance, guiding optimal therapy sequencing.
Area of Science:
- Oncology
- Endocrinology
- Pharmacology
Background:
- Hormone receptor-positive breast cancer (HR+ BC) is often treated with endocrine therapy.
- Endocrine resistance is a significant challenge in managing metastatic HR+ BC.
- Novel therapeutic strategies are needed to overcome endocrine resistance.
Purpose of the Study:
- To review current treatment strategies for metastatic HR+ BC.
- To discuss the role of newer agents like CDK4/6 inhibitors.
- To explore the potential of PI3K and mTOR inhibitors in endocrine-resistant settings.
Main Methods:
- Literature review of clinical trials and studies.
- Analysis of treatment outcomes for various drug combinations.
- Evaluation of factors influencing therapeutic sequencing.
Main Results:
- CDK4/6 inhibitors have demonstrated significant improvements in progression-free survival.
- PI3K and mTOR inhibitors are being investigated as subsequent lines of therapy.
- Optimal sequencing depends on patient-specific factors.
Conclusions:
- CDK4/6 inhibitors represent a major advancement in metastatic HR+ BC treatment.
- Targeted therapies like PI3K and mTOR inhibitors offer promise for endocrine resistance.
- Personalized treatment sequencing is crucial for maximizing patient benefit.
Related Concept Videos
Endocrine Signaling
Intracellular Hormone Receptors
Types of Hormones
Hormonal Regulation
Hormonal Regulation
Treatment Resistant Cancers


